0001358403-16-000273.txt : 20160923
0001358403-16-000273.hdr.sgml : 20160923
20160923185618
ACCESSION NUMBER: 0001358403-16-000273
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160921
FILED AS OF DATE: 20160923
DATE AS OF CHANGE: 20160923
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001358403
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 201450200
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
BUSINESS PHONE: (832) 384-1100
MAIL ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
FORMER COMPANY:
FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Slawin Kevin M.
CENTRAL INDEX KEY: 0001626808
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36783
FILM NUMBER: 161900755
MAIL ADDRESS:
STREET 1: C/O BELLICUM PHARMACEUTICALS, INC.
STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
4
1
wf-form4_147467136560781.xml
FORM 4
X0306
4
2016-09-21
0
0001358403
BELLICUM PHARMACEUTICALS, INC
BLCM
0001626808
Slawin Kevin M.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON
TX
77030
1
1
0
0
Chief Technology Officer
Common Stock
2016-09-21
4
S
0
100
20.04
D
95464
D
Common Stock
2016-09-21
4
S
0
100
20.04
D
366940
I
By the Jordana Slawin 2012 Family Trust
Common Stock
398067
I
By the Kevin Slawin 2009 Family Trust
Common Stock
2016-09-23
4
S
0
11258
20.1234
D
84206
D
Common Stock
2016-09-23
4
S
0
11958
20.1146
D
354982
I
By the Jordana Slawin 2012 Family Trust
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 23, 2016 by the Reporting Person.
The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Dr. Kevin M. Slawin
2016-09-23